[
  {
    "ts": "2025-11-26T10:17:00+00:00",
    "headline": "US STD Diagnostics Market Forecast and Company Analysis 2025-2033 Featuring Abbott, F. Hoffmann-La Roche, Hologic, BD and Co, Danaher, Siemens, bioMerieux, Thermo Fisher Scientific, Qiagen, Bio-Rad",
    "summary": "The United States STD Diagnostics Market is set to grow from US$ 5.06 billion in 2024 to US$ 8.49 billion by 2033, achieving a CAGR of 5.91% from 2025 to 2033. Key growth drivers include rising STD prevalence, technological advancements, increased awareness, and supportive government initiatives. Rapid point-of-care tests and molecular diagnostics are gaining traction, while high costs and regulatory hurdles persist as challenges. Major markets like California, Texas, New York, and Florida lead",
    "url": "https://finance.yahoo.com/news/us-std-diagnostics-market-forecast-101700596.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "a2226b4c-5413-3331-af08-a414cc2177ba",
      "content": {
        "id": "a2226b4c-5413-3331-af08-a414cc2177ba",
        "contentType": "STORY",
        "title": "US STD Diagnostics Market Forecast and Company Analysis 2025-2033 Featuring Abbott, F. Hoffmann-La Roche, Hologic, BD and Co, Danaher, Siemens, bioMerieux, Thermo Fisher Scientific, Qiagen, Bio-Rad",
        "description": "",
        "summary": "The United States STD Diagnostics Market is set to grow from US$ 5.06 billion in 2024 to US$ 8.49 billion by 2033, achieving a CAGR of 5.91% from 2025 to 2033. Key growth drivers include rising STD prevalence, technological advancements, increased awareness, and supportive government initiatives. Rapid point-of-care tests and molecular diagnostics are gaining traction, while high costs and regulatory hurdles persist as challenges. Major markets like California, Texas, New York, and Florida lead",
        "pubDate": "2025-11-26T10:17:00Z",
        "displayTime": "2025-11-26T10:17:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/4c018338adae3a4e1c2b03ee4853aa6f",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "U.S. STD Diagnostics Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WKlMszOzCI8U2a7zewvJHA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/4c018338adae3a4e1c2b03ee4853aa6f.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hoCXHDbPw3AQmQG0fYrtZQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/4c018338adae3a4e1c2b03ee4853aa6f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/us-std-diagnostics-market-forecast-101700596.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/us-std-diagnostics-market-forecast-101700596.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            },
            {
              "symbol": "HOLX"
            },
            {
              "symbol": "SIEGY"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "DHR"
            },
            {
              "symbol": "TMO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-26T11:58:00+00:00",
    "headline": "DuPont Can Become a ‘Compounder.’ Why the Stock Could Gain 20%.",
    "summary": "Deutsche Bank analyst David Begleiter reiterated his Buy rating on the shares. His price target is $46",
    "url": "https://www.barrons.com/articles/dupont-stock-price-compounder-buy-fd98b593?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "d3494eac-f62d-3694-9869-d4e6def1e34f",
      "content": {
        "id": "d3494eac-f62d-3694-9869-d4e6def1e34f",
        "contentType": "STORY",
        "title": "DuPont Can Become a ‘Compounder.’ Why the Stock Could Gain 20%.",
        "description": "",
        "summary": "Deutsche Bank analyst David Begleiter reiterated his Buy rating on the shares. His price target is $46",
        "pubDate": "2025-11-26T11:58:00Z",
        "displayTime": "2025-11-26T11:58:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/d3494eac-f62d-3694-9869-d4e6def1e34f/dupont-can-become-a.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/b7a80c156b27cd53611d3053cb8b2646",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZPW68k_w8V.kDbg2Hwe76g--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/b7a80c156b27cd53611d3053cb8b2646.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NBSYPC.FnWLjcBfvEwTKbA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/b7a80c156b27cd53611d3053cb8b2646.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/dupont-stock-price-compounder-buy-fd98b593?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DD"
            },
            {
              "symbol": "QUCOF"
            },
            {
              "symbol": "BRK-B"
            },
            {
              "symbol": "DOW"
            },
            {
              "symbol": "DHR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-26T12:48:29+00:00",
    "headline": "Danaher Stock: Is DHR Underperforming the Healthcare Sector?",
    "summary": "Despite Danaher’s underperformance relative to the healthcare sector, Wall Street analysts remain strongly optimistic about the stock’s prospects.",
    "url": "https://www.barchart.com/story/news/36324811/danaher-stock-is-dhr-underperforming-the-healthcare-sector",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "5255f6f2-7d43-331f-af6a-2e8c18bc57a9",
      "content": {
        "id": "5255f6f2-7d43-331f-af6a-2e8c18bc57a9",
        "contentType": "STORY",
        "title": "Danaher Stock: Is DHR Underperforming the Healthcare Sector?",
        "description": "",
        "summary": "Despite Danaher’s underperformance relative to the healthcare sector, Wall Street analysts remain strongly optimistic about the stock’s prospects.",
        "pubDate": "2025-11-26T12:48:29Z",
        "displayTime": "2025-11-26T12:48:29Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/7ef65c81c3a0a3eb5bd360381ab9fc7f",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Danaher Corp_ logo on vial-by Melnilov Dmitriy via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gKiE3umLBtKS78lJQ2syZw--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/7ef65c81c3a0a3eb5bd360381ab9fc7f.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lDJF5LZjUqFowtQLfYq2Mw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/7ef65c81c3a0a3eb5bd360381ab9fc7f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/36324811/danaher-stock-is-dhr-underperforming-the-healthcare-sector",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/danaher-stock-dhr-underperforming-healthcare-124829098.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DHR"
            },
            {
              "symbol": "XLV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-26T16:30:07+00:00",
    "headline": "Revvity (RVTY) Up 9.5% Since Last Earnings Report: Can It Continue?",
    "summary": "Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finance.yahoo.com/news/revvity-rvty-9-5-since-163007979.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "1103c935-b42e-37a5-92a4-937679231226",
      "content": {
        "id": "1103c935-b42e-37a5-92a4-937679231226",
        "contentType": "STORY",
        "title": "Revvity (RVTY) Up 9.5% Since Last Earnings Report: Can It Continue?",
        "description": "",
        "summary": "Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
        "pubDate": "2025-11-26T16:30:07Z",
        "displayTime": "2025-11-26T16:30:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/c65fb4556b91b6c9dc83e4eff25fede0",
          "originalWidth": 3000,
          "originalHeight": 2351,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/22J0oUBDggIxRsu_SBEo3A--~B/aD0yMzUxO3c9MzAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/zacks.com/c65fb4556b91b6c9dc83e4eff25fede0.cf.webp",
              "width": 3000,
              "height": 2351,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/c871s3MwhyhBJ_fCBFL4cw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c65fb4556b91b6c9dc83e4eff25fede0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/revvity-rvty-9-5-since-163007979.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/revvity-rvty-9-5-since-163007979.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RVTY"
            },
            {
              "symbol": "DHR"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]